208 related articles for article (PubMed ID: 22126137)
21. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
22. Role of bisphosphonates in prostate cancer.
Saad F; Schulman CC
Eur Urol; 2004 Jan; 45(1):26-34. PubMed ID: 14667511
[TBL] [Abstract][Full Text] [Related]
23. Collagen derived serum markers in carcinoma of the prostate.
Rudnicki M; Jensen LT; Iversen P
Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
[TBL] [Abstract][Full Text] [Related]
24. Antiandrogen withdrawal syndrome with nilutamide.
Huan SD; Gerridzen RG; Yau JC; Stewart DJ
Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies.
Okamura T; Akita H; Tatsura H; Kawai N; Nagata D; Azemoto M; Iwase Y; Kohri K
Cancer Detect Prev; 2003; 27(1):14-8. PubMed ID: 12600412
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Zheng M;
J Natl Cancer Inst; 2004 Jun; 96(11):879-82. PubMed ID: 15173273
[TBL] [Abstract][Full Text] [Related]
27. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone.
Saad F
Clin Prostate Cancer; 2002 Dec; 1(3):145-52. PubMed ID: 15046689
[TBL] [Abstract][Full Text] [Related]
29. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
Akimoto S; Furuya Y; Akakura K; Ito H
Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
[TBL] [Abstract][Full Text] [Related]
30. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Pitts WR
J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
[No Abstract] [Full Text] [Related]
31. Correlation between bone metabolic markers and bone scan in prostatic cancer.
Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
[TBL] [Abstract][Full Text] [Related]
32. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study.
Zhang F; Dong Y; Chen F; Niu M; Liu Z; Wang C
Arch Esp Urol; 2024 Apr; 77(3):242-248. PubMed ID: 38715164
[TBL] [Abstract][Full Text] [Related]
33. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for.
Debruyne FM
Eur Urol; 1996; 29 Suppl 2():34-6. PubMed ID: 8717460
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
Noguchi M; Yahara J; Noda S
Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
[TBL] [Abstract][Full Text] [Related]
35. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Prostate; 1999 Jan; 38(1):28-34. PubMed ID: 9973106
[TBL] [Abstract][Full Text] [Related]
36. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Bankhead C
J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
[No Abstract] [Full Text] [Related]
37. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer.
Michaelson MD; Marujo RM; Smith MR
Clin Cancer Res; 2004 Apr; 10(8):2705-8. PubMed ID: 15102674
[TBL] [Abstract][Full Text] [Related]
38. Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain.
Magnusson P; Larsson L; Englund G; Larsson B; Strang P; Selin-Sjögren L
Clin Chem; 1998 Aug; 44(8 Pt 1):1621-8. PubMed ID: 9702948
[TBL] [Abstract][Full Text] [Related]
39. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Janknegt RA
Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
[TBL] [Abstract][Full Text] [Related]
40. [Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer].
Morote Robles J; Reig Ruiz C; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
Actas Urol Esp; 1993 May; 17(5):292-4. PubMed ID: 7688176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
